Here are five things to know:
1. Northland Securities will now cover K2M.
2. The company issued an “outperform” rating.
3. The price objective on the stock is $31.
4. Barclays also raised K2M’s price target from $27 to $28.
5. K2M’s market cap is $988.2 million.
More articles on orthopedic devices:
LDR gets “Outperform” rating—5 key notes
Spinal Kinetics M6 disc replacement: Grood results 2 years postop
Allegheny Health Network incorporates MAKOplasty
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
